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Abstract
Background: Cerebral palsy (CP) may cause severe spasticity, requiring neurosurgical procedures. The most common 
neurosurgical procedures are continuous infusion of intrathecal baclofen and selective dorsal rhizotomy. Both are 
invasive and complex procedures. We hypothesized that a percutaneous radiofrequency lesion of the dorsal root 
ganglion (RF-DRG) could be a simple and safe alternative treatment. We undertook a pilot study to test this hypothesis.
Methods: We performed an RF-DRG procedure in 17 consecutive CP patients with severe hip flexor/adductor spasms 
accompanied by pain or care-giving difficulties. Six children were systematically evaluated at baseline, and 1 month 
and 6 months after treatment by means of the Modified Ashworth Scale (MAS), Gross Motor Function Measure (GMFM) 
and a self-made caregiver's questionnaire. Eleven subsequent children were evaluated using a Visual Analogue Scale 
(VAS) for spasticity, pain and ease of care.
Results: A total of 19 RF-DRG treatments were performed in 17 patients. We found a small improvement in muscle 
tone measured by MAS, but no effect on the GMFM scale. Despite this, the caregivers of these six treated children 
unanimously stated that the quality of life of their children had indeed improved after the RF-DRG. In the subsequent 
11 children we found improvements in all VAS scores, in a range comparable to the conventional treatment options.
Conclusion: RF-DRG is a promising new treatment option for severe spasticity in CP patients, and its definitive 
effectiveness remains to be defined in a randomised controlled trial.
Background
Cerebral palsy (CP) is a central nervous system deficit
resulting from a non-progressive lesion in the developing
brain. Although these brain lesions are static, the move-
ment disorders that arise are not unchanging and are
characterised by atypical muscle tone, posture and move-
ment [1]. The spastic motor type is the most common
form of CP and its conventional therapeutic management
may include splinting/casting, physiotherapy, occupa-
tional therapy, oral spasmolytics and anti-dystonic drugs,
Botulinum Toxin-A (BTX-A) injections, orthopaedic pro-
cedures, and neurosurgical procedures. The most com-
mon neurosurgical procedures are continuous infusion of
intrathecal Baclofen (ITB) and selective dorsal rhizotomy
(SDR). Since its first description by Foerster in 1913, SDR
has been modified by various researchers and has
become a standard neurosurgical procedure to treat spas-
ticity in CP patients [2-5]. However, as multiple-level
laminectomies at the L1-S1 level are often required, the
procedure is invasive and can lead to complications as
transient urinary incontinence, chronic low back pain
and spinal deformity [6-9]. Considerable cooperation of
the patient is required to successfully complete the post-
operative rehabilitation program.
An alternative for the SDR is a radiofrequency lesion of
the dorsal root ganglion (RF-DRG), which has been used
to treat chronic pain for over 30 years [10]. The RF-DRG
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is a simple and safe treatment with little side effects [11-
13]. In the 1980's several authors reported that the same
procedure might be used to treat adult patients with spas-
ticity [14,15]. More recently, we were able to show that an
R F - D R G  a l l e v i a t e s  h i p  f l e x o r  s p a s m s  i n  2  C P  p a t i e n t s
[16]. CP patients can also suffer from severe pain through
spasticity, bone deformities or joint subluxation, espe-
cially hip displacement and dislocation [17,18], which
may lead, through an enhanced processing of afferent
information within the spinal cord, to secondary pain
[19].
We thus hypothesized that an RF-DRG may alleviate
spasticity and pain in CP patients, and we tested this
hypothesis in a pilot study of 17 patients.
Methods
Children with spasticity from CP were seen by a multi-
disciplinary spasticity management team (child neurolo-
gist, orthopaedic surgeon, and physician assistant child
neurology) in the Maastricht University Medical Cen-
tre(JV, LvR, HS, DS). Individual treatment goals were
determined after a careful assessment of the aetiology,
functional ability and associated impairments as a result
of the spasticity. The RF-DRG treatment was considered
in children with severe hip flexor/adductor spasms
accompanied by pain or care giving difficulties. The pro-
cedure was approved by the Institutional Review Board of
the Maastricht University Medical Centre, according to
Dutch governmental regulations and informed consent
from the caregivers was obtained for each patient.
A total of 17 children were treated with RF-DRG (tables
1 and 2). The severity of CP was based on the Gross
Motor Function Classification System (GMFCS) for CP
[20,21]. Hip(sub)luxation was classified according to the
morphological hip classification system proposed by
Robin et al [22].
Six children (group A) were systematically evaluated at
baseline, and 1 month and 6 months after treatment
(table 1, table 3). In this group all assessments were per-
formed by a physical therapist. The Modified Ashworth
Scale (MAS) was used for the assessment of changes in
muscle tone [23]. In the MAS the muscle tone is scored
on a 6 point scale, in which "0" represents no hypertonia
or no increase of muscle tone and "4" represents severe
hypertonia and severe stiffness of the extremities. In each
patient hip flexion and adduction, knee flexion and
extension and dorsal and plantar flexion in the ankle were
tested bilaterally. Functional improvement was assessed
using the Gross Motor Function Measure (GMFM), a
widely used scale consisting of 5 different locomotor
domains to evaluate treatment of spasticity in children
with CP [24-26]. Furthermore, we developed a more
extensive questionnaire for caregivers. Besides items on
pain, several items of daily activities of life, like dressing,
undressing and bathing, were investigated. Data of the 6
systematically evaluated children were statistically ana-
lyzed using a students T-test and a Wilcoxon signed rank
test. A p value of < 0.05 was considered to be statistically
significant. All data are represented as means and stan-
dard error of means (SEM).
The following 11 children (group B) were evaluated at 6
weeks and 3 months using a Visual Analogue Scale (VAS),
which was used to measure the severity of the individu-
ally formulated problems. We changed the evaluation
methods, as we were not able to detect the kind of change
that the caregivers unanimously did notice. Furthermore,
we learned from literature that the MAS and the GMFM
are not indicated to measure changes in these severely
handicapped children [27-29]. Instead we used a VAS,
which is a valid pain-rating instrument [30]. The VAS
used in pain assessment is a straight 10 cm horizontal line
with anchor points of no pain (score 0) and unbearable
pain (score 10). For our study we changed the anchor
points into very satisfied (score 0) and very dissatisfied
(score 10) to use the VAS uniformly for individually
defined problems [[31,32], figure 1]. A VAS score for
spasticity, pain, and ease of care was given by the caregiv-
ers, since the majority of the CP patients were severely
mentally handicapped. Usually the patient and his/her
caregiver(s) are the best judges of the severity of the
impairments accompanying spasticity, as they are the
only people who can assess its impact on the daily life of
the patient [33]. Caregivers of children with profound
impairments note changes in function far more accu-
rately than staff workers [34].
RF-DRG procedure
All patients were treated in our outpatient clinic, and RF-
DRG was performed as described [12,13,35]. Under gen-
eral anaesthesia, the patients were placed in prone posi-
tion on an operating table. The level to be treated was
based on clinical symptoms; afterwards stimulation was
used to verify these levels.
The procedure was performed in tunnel vision, a tech-
nique for entering the electrode in the direct vision of the
X-rays. Therefore, the C-arm (Ziehm electronics) was
adjusted in such a way that the X-rays ran parallel to the
end plates of the relevant level. Thereafter, the C-arm was
rotated until the processus spinosus projected over the
contralateral facet column. With the C-arm in this pro-
jection, the injection point was found by projecting a
metal ruler over the lateral part of the foramen interver-
tebrale.
A 10-cm long, 22-G needle SMK-5 mm tip was inserted
locally in the direction of the X-rays. Thereafter, the
direction was corrected in such a way that the needle was
being projected as a point on the screen. The direction of
the radiation beam was now modified to a profile (lateral)




























































































Table 1: Summary of 6 patients (Group A) treated with RF-DRG and evaluated systematically









spast pain care spast pain care spast pain care Left Right
1 f 6 Asphyxia V L1-2 L1-2 ▪▪ + no + no IV III
2 f 12 Trauma V L1-4 L1-4 ▪▪ ▪+ + + no + + + no III I
3 f 16 Premature V - L1-3 ▪▪ + + no + + no II V
4 f 11 Asphyxia V L2-4 L2-4 ▪ + no + no II IV
5 m 7 Premature V L1-2 - ▪ - yes + no V III
6f 1 4 A s p h y x i a V - L 1 - 3 ▪▪ ▪+ + + no + + + no III V
m: male; f: female; yr: years; GMFCS: Gross Motor Function Classification System; spast: spasticity
▪: indication
Improvement: +/-: summary of improvement/worsening measured by the self-made questionnaire




























































































Table 2: Summary of 11 patients (Group B) treated with RF-DRG and evaluated by VAS.
m/f Age (yr) SCPE GMFCS 
Score
RF-DRG-left RF-DRG-right Indication VAS pre Improvement VAS post Δ-VAS Side-effects Hip morphology
spast pain care spast pain care left right
1f 1 8 2 V L 1 - 3 - ▪ 8 + 2 6 no III V
2f 2 2 2 V L 1 - 4 - ▪▪ 10 + + 1.5 8.5 no ns ns
3 f 10 2 V L1-2 L1-2 ▪▪ 10 + 8 2 no V III
4m 1 6 2 V L 1 - 3 - ▪ 7+3 4 n o I I V
5m 1 6 2 V L 1 - 4 - ▪▪ 8.2 + 1.6 6.6 no IV V
6m 7 2 V - L 1 - 3 ▪ ns ns yes 0 III
7m 5 2 V L 1 - 3 L 1 - 3 ▪▪ ns + ns no IV IV
8f 1 1 2 V L 1 - 2 - ▪ 6+2 4 n o * I I
9f 1 0 2 V L 1 - 2 - ▪▪▪ 8+ + 5 . 5 2 . 5 n o I I
f1 2 2 V L 1 - 2 - ▪▪▪ 8+ + 5 3 n o I I
f1 4 2 V L 1 - 2 - ▪▪▪ 10 10 0 no I I
10 m 5 2 V L1-4 L1-4 ▪▪ ns + ns no II V
11 f 16 2 V L1-4 L1-4 ▪▪▪ 8.7 + + + 3.1 5.6 no ns ns
m: male; f: female; yr: years; SCPE: surveillance for cerebral palsy in Europe classification: (1) unilateral; (2) bilateral
GMFCS: Gross Motor Function Classification System * Osteomyelitis; ns: not scored;
▪: indication
+: domain in which the improvement measured by VAS was notedVles et al. BMC Neurology 2010, 10:52
http://www.biomedcentral.com/1471-2377/10/52
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located in the craniodorsal part of the foramen interver-
tebrale (Figure 2a).
In an AP view, the course of a small amount of contrast
agent was followed with "real-time imaging"; it should
spread out laterocaudally along the spinal nerve (Figure
2b). The stylet was removed and exchanged for the radio
frequent probe. After checking the impedance (an indica-
tor for the type of tissue next to the cannula tip), electrical
stimulation was started at a rate of 2 Hz and the corre-
sponding muscles were observed for contractions. At 2
Hz stimulation motor contractions should be observed in
the area of the relevant muscles at a threshold between
0.4-0.8 Volts. 1 ml local anaesthetic solution (bupivacain
0.5%) was injected and radio frequent current was then
led through the electrode in order to increase the temper-
ature to 67°C for 60 seconds. Total operating time,
including anaesthesia, was about 45 minutes. All patients
were discharged from the clinic the same day after full
recovery from the anaesthesia.
Results
A total of 19 RF-DRG treatments were performed in 17
patients. One patient received three interventions, as the
effects gradually wore off. A summary of the clinical data,
including treated levels and outcome measures, are given
in table 1 (group A: 6 patients) and table 2 (group B: 11
patients). In 2 patients a transient increase in pain after
the RF-DRG procedure was noted, and 1 patient was suc-
cessfully treated with Gabapentine for 4 weeks. No fur-
ther side effects (e.g. dysaesthesia or excessive weakness
in the treated limbs) were reported. No significant differ-
ences were observed between the different lumbar levels
for both the impedance and the stimulation threshold.
Group A
In the first six systematically evaluated children (table 1)
an improvement in muscle tone after RF-DRG was
detected on both the short (4 weeks) and long (6 months)
term using the MAS. Especially the right hip adductors
showed improvement on the MAS which went from 2.2
+/- 0.5 before RF-DRG to 0.5 +/- 0.2 four weeks after RF-
DRG and 1.0 +/- 0.4 six months after RF-DRG (table 3).
Due to the small sample size, no comment on the lack of
significance of a null result can be given.
Using the GMFM no improvement was observed after
RF-DRG treatment. At baseline a mean total score
Table 3: Modified Ashworth Scale scores of the first 6 patients: pre-operative, post-operative 4 weeks and 6 months.
Hipflexion Hip adduction Knee flexion Knee extension Ankle dorsal flexion Ankle plantar flexion
Pt L R L R L R L R L R L R
1 Pre 1+ 1+ 1 2 1 2 0 0 3 3 0 0
P o s t 4 w 1 1 0011002 2 0 0
P o s t 6 m 1 0 1110003 2 0 0
2 P r e 0 0 1300113 3 0 0
P o s t 4 w 0 0 1100111 1 0 0
P o s t 6 m 0 0 1100001 1 0 0
3P r e011 +2 1 1 2 2 3 3 0 1
Post4w 0 1+ 1+ 1 1+ 1 2 1+ 2 2 0 0
P o s t 6 m 2 1 2121002 2 0 0
4 P r e 0 0 111 + 1 + 330 0 1 1
P o s t 4 w 0 0 0022001 0 0 0
P o s t 6 m 1 1 0022001 1 0 0
5 Pre 2 0 0 1 0 1+ 2 2 2 2 1+ 1+
P o s t 4 w 1 1 0112141 1 2 3
P o s t 6 m 2 0 0024002 3 0 0
6 P r e 3 3 4444444 3 4 3
P o s t 4 w 0 0 1031232 1 + 2 2
P o s t 6 m 3 3 4333004 4 4 4
Mean Pre 1 0.83 1.33 2.17 1.17 1.5 2 2 2.5 2.33 1 1
Post4w 0.33 0.5 0.75 0.5 1.33 1.17 1 1.5 1.5 1.17 1.67 0.83
Post6m 1.5 0.83 1.33 1.0 1.67 1.67 0.17 0 2.17 2.17 0.67 0.67Vles et al. BMC Neurology 2010, 10:52
http://www.biomedcentral.com/1471-2377/10/52
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including all 5 domains of 17.2% +/- 6 was found. After 4
weeks the score was 17.3% +/- 7 and after 6 months the
score was 16.2% +/- 6.
Using the caregiver's questionnaire, an improvement in
ease and quality of care and pain was detected. Although
statistically not significant, in four patients pain in the
lower extremities decreased, at both 4 weeks and 6
months. In one patient there was no change in pain and
in another patient pain increased at 4 weeks but
decreased at 6 months when compared to the baseline.
Group B
Because of the abovementioned results we switched to a
VAS to evaluate the initiated treatment in the subsequent
patients. This score was available in 8 out of the 11
patients. The missing values are due to the fact that some
caregivers did not feel comfortable judging their own
child in a numerical way. During outpatient follow up, the
evaluation of the VAS scores showed improvement in
most of the defined goals in most children (table 2). Most
parents reported that the positive effects of the RF-DRG
lasted at least 6-9 months.
In one patient (no. 9), the VAS score showed no change
after the third procedure. Her flexor spasms were then
successfully treated with Botulinum Toxin-A injections in
the iliopsoas and adductor muscles (Dysport, Ipsen).
Discussion
T o t es t  our  h ypo t hes is  t ha t  RF-DR G  m a y be  a  se ri ous
treatment option for severe spasticity in children with CP,
we undertook a pilot study in 17 patients. Our primary
treatment goal was improvement of well-being and ease
of care of CP patients with severe hip flexor/adductor
spasms and pain. Our first 6 consecutively treated
patients (Group A) were evaluated at baseline, 1 month
after treatment and 6 months after treatment with the
GMFM and the MAS. We found a small improvement in
muscle tone by the MAS, but no effect on the GMFM
scale. Despite this, the caregivers of these six treated chil-
dren unanimously stated that the quality of life of their
children had indeed improved after the RF-DRG (data
not shown, summary represented by +/- in table 1). This
disagreement between the MAS and the judgement of the
caregivers highlights the difficulties measuring change in
these severely handicapped children. The MAS as a
method for the evaluation of the treatment of spasticity in
children with CP has been disputed before, although in
adult populations the reliability of the MAS has been
demonstrated [27]. In a study in children with moderate
to severe spasticity, a wide variability in test-retest results
was reported for the MAS [28]. The assumption that the
MAS purely measures spasticity is not entirely right. The
MAS measures a broader set of neural and musculoskele-
tal factors of non-velocity-dependent hypertonia in addi-
tion to spasticity itself [29].
Furthermore, we added up the MAS scores of different
muscles to produce a summed Ashworth score, in order
t o  c o m p a r e  w i t h  m o s t  p r e v i o u s  s t u d i e s .  H o w e v e r ,  t h i s
might be methodologically incorrect because the Ash-
worth score is an ordinal level measure [36].
For the next 11 patients we thus changed our evaluating
system: instead of the MAS and the GMFM, we asked the
caregivers to give a VAS score for spasticity, pain and ease
of care at different time points. Using this outcome mea-
sure we were able to show a significant improvement in
spasticity, pain and ease of care after an RF-DRG proce-
dure, lasting up to 9 months. In two patients we found a
transient increase in pain, for which 1 patient received
Gabapentine for 4 weeks. This is a known transient pro-
cedure related event [37]. Although this was not a con-
trolled study, the amount of improvement in VAS scores
is in the same range as in conventional treatments, e.g.
Figure 1 The VAS device. Score 0/"geen": Very satisfied. Score 10/
"meest": Very dissatisfied.
Questions: 1. What overall score would you give your child when con-
sidering pain, ease of care and spasticity?
2. In which domain(s) did you notice this improvement: pain, ease of 
care, spasticity? (See table 2)
Figure 2 Photomicrograph showing the position of an RF elec-
trode a: lateral view and b: anterior- posterior view after injection 
of Omnipaque.Vles et al. BMC Neurology 2010, 10:52
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intrathecal baclofen (ITB) and SDR [31,38]. RF-DRG is
thus a promising new treatment option for severe spastic-
ity in CP patients, and its definitive effectiveness remains
to be defined in a randomised controlled trial. It is less
invasive and has probably less side effects than ITB and
SDR, but its main disadvantage in this patient population
is, of course, the temporary character of its effects. In this
regard RF-DRG resembles BTX-A treatment, but its main
advantage over this therapeutic option is its strong pain-
reducing effect. Theoretically, repetitive RF-DRG's may
lead to dysesthesias and causalgias, but we have not seen
this in the one patient we treated three times [35]. To pre-
vent this possible side effect, more definitive effects of
RF-DRG might perhaps be achieved with higher radiofre-
quency currents and temperatures during the procedure.
Our pilot study does highlight the methodological
problem of evaluating treatment effects in children with
CP. As we were not able to conduct an extensive battery
of clinical tests in our pilot study, we had to select a few
outcome measures. Using the MAS and the GMFM, we
were not able to detect any beneficial effects, which is in
line with other studies [33]. We had to resort to a VAS to
find improvements in the condition of treated patients. In
r e t r o s p e c t  w e  s h o u l d  a l s o  h a v e  i n c l u d e d  t h e  P e d i a t r i c
Evaluation of Disability Inventory (PEDI), which is a
generic standardised instrument used by the multidisci-
plinary team for evaluating functional performance, pro-
gramme monitoring, documentation of functional
development and clinical decision-making [31,38,39].
The exact mechanism of action of an RF-DRG lesion
remains unknown. W e recently reported an increase of
proliferation inside the dorsal root ganglion after RF-
DRG adjacent to the ganglion without signs of neural tis-
sue damage (e.g. necrosis) inside the ganglion [40]. For
years, the only mode of action of a radiofrequency lesion
was thought to be through nerve damage due to thermo-
coagulation [41]. Recent experiments with pulsed radiof-
requency treatment (a high-frequency current delivered
in bursts of 20 ms followed by a silent period of 480 ms,
during which the generated heat is washed out) suggest
that thermocoagulation is not the only mode of action
[41,42]. A late and temperature-independent increase in
the expression of the immediate early c-fos gene within
the rat spinal cord was found after exposure of the cervi-
cal dorsal root ganglion to continuous radiofrequency
(67°C) and pulsed radiofrequency current [43]. In one
model of spasticity, the locomotor abnormalities are
thought to be the result of hyperexcitability of spinal
interneurons involved in the spinal stretch reflex [44].
Reduction of spinal input through de-afferentation is
then the basic mechanism of RF-DRG.
Conclusion
Our pilot study on RF-DRG in 17 CP patients with severe
hip flexor/adductor spasms and pain shows that it may
improve spasticity, pain, and ease of care, with a duration
of up to 9 months. As the amount of improvement is in
the same range as in conventional treatments, RF-DRG is
thus a promising new treatment option for severe spastic-
ity in CP patients, and its definitive effectiveness remains
to be defined in a randomised controlled trial. The main
advantages are the less invasive character of RF-DRG
compared to the SDR with the potential benefit of a
shorter hospitalisation period, and its clear pain-reducing
effect.
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